Binding of Bruton's Tyrosine Kinase to Fyn, Lyn, Or Hck Through A

Total Page:16

File Type:pdf, Size:1020Kb

Binding of Bruton's Tyrosine Kinase to Fyn, Lyn, Or Hck Through A View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Caltech Authors - Main Proc. Nati. Acad. Sci. USA Vol. 91, pp. 8152-8155, August 1994 Cell Biology Binding of Bruton's tyrosine kinase to Fyn, Lyn, or Hck through a Src homology 3 domain-mediated interaction GENHONG CHENG, ZHENG-SHENG YE, AND DAVID BALTIMORE The Rockefeller University, 1230 York Avenue, New York, NY 10021 Contributed by David Baltimore, April 25, 1994 ABSTRACT Bruton's tyrosine kinase (Btk) is a recently MATERIALS AND METHODS described B-cell-specific tyrosine kinase. Mutations in this gene Cloning. To isolate Btk cDNA clones, oligonucleotides lead to human X chromosome-linked agammaglobulinemia corresponding to either the amino terminus or carboxyl and murine X-linked inmunodeficiency. Although genetic terminus of the human Btk protein were made according to evidence strongly suggests that Btk plays a crucial role in the published sequences (5) and used to probe duplicate lifts B-lymphocyte differentiation and activation, its precise mech- of A phage plaques on filters. Ten independent doubly pos- anism of action remains unknown, primarily because the itive clones were isolated from -1 x 106 phage plaques. We proteins that it interacts with have not yet been identified. partially sequenced these 10 cDNA clones and found that Here, we show that Btk interacts with Src homology 3 domains they all contained the full-length Btk coding sequence. A of Fyn, Lyn, and Hck, protein-tyrosine kinases that get acti- DNA fragment containing the amino-terminal portion of a vated upon stimulation of B- and T-cell receptors. These mouse Btk cDNA clone was constructed in the EG202 interactions are mediated by two 10-aa motifs in Btk. An vector, which contains the LexA DNA binding domain as its analogous site with the same specificity is also present in Itk, the amino terminus (12). When this LexA-BtkN bait, along with T-cell-specific homologue of Btk. Our data extend the range of the reporter plasmid pSH18-34 containing the LexA binding interactions mediated by Src homology 3 domains and provide site driving the lacZ gene, was transformed into the yeast an indication of a link between Btk and established signaling strain EGY48 (MATa, trpl, ura3, his, Leu2.plexAop6-leu2), pathways in B lymphocytes. colonies required leucine to grow and did not turn blue on 5-bromo-4-chloro-3-indolyl -D-galactoside (X-Gal) medium. Thus, the bait did not contain intrinsic transactivation po- Tyrosine phosphorylation is one of the earliest events during tential and was suitable for library screening. Library plas- B-lymphocyte activation. When the B-cell receptors on the mids (pJG4-5) containing the B42 acidic activation domain surface of resting splenic B cells or certain B-cell lines are and cDNAs derived from HeLa cells were then transformed cross-linked by anti-immunoglobin antibody, within 10 min into the yeast clone carrying both the LexA-BtkN bait and more than a dozen proteins become phosphorylated on the reporter plasmid pSH18-34. A total of 4.5 x 106 yeast tyrosine (1). Among these are certain Src family tyrosine transformants were selected on Ura-, His-, Trp-, and Leu- kinases such as Fyn, Lyn, and Hck, which are associated X-Gal/galactose plates. Approximately 3000 colonies grew in with the B-cell receptor complex in resting B cells (2-4). How the absence of leucine, but only 90 turned blue. Because the clustering of the B-cell receptor complex might lead to library vector pJG4-5 used here contained a galactose- activation of protein-tyrosine kinases remains to be shown. inducible promotor, colonies of authentic interacting clones Recently, a kinase called Bruton's tyrosine kinase (Btk) has should turn blue when galactose but not glucose is used as a been discovered, which seems to play a central role in B-cell carbon source. Colony replicas of the 90 clones were plated signaling events. Mutations of this gene are responsible for onto both X-Gal/glucose and X-Gal/galactose plates, and 70 X-linked agammaglobulinemia, a severe human immunode- showed unambiguous galactose-dependent blue color. Plas- ficiency disease, and murine X-linked immunodeficiency mid DNAs were isolated from 12 of these clones, and library (5-8). It belongs to a subgroup of Src-related kinases includ- plasmids were selected through their tryptophan synthase ing Itk found in T cells and Tec II found in liver and myeloid gene. They were purified and reintroduced back into yeast cells (9, 10). Like all other members of the Src family, Btk strain EGY48 along with the reporter plasmid pSH18-34 plus contains a kinase a Src homology (SH) 2 either the pEG202-lexA-BtkN or pEG202 vector. Colonies tyrosine domain, were replicated onto either glucose/X-Gal or galactose/X- domain, and an SH3 domain. The long amino-terminal region Gal plates. Clones with specific Btk-interacting proteins in Btk is similar to those in Itk and Tec II but is not shared showed blue color on galactose/X-Gal plates only with by other Src kinases and contains an apparent pleckstrin pEG202-LexA-BtkN as bait. The insert from one clone was homology (PH) domain (11). To understand how Btk is sequenced and found to correspond to the amino-terminal involved in B-cell development and activation, we have region of the human FYN gene. searched for proteins with which Btk might interact. We The Source ofthe Various SH3 Domains. GST-Abl-SH3 and show that Btk has a specific binding site that interacts with GST-Src-SH3 have been described (13). The sequences cod- the SH3 domains of the Src-related Fyn, Lyn, and Hck ing for the SH3 domains of mouse Btk (amino acid residues kinases. These interactions occur through two proline- 218-276), bovine Blk (55-113), and chicken Fyn (80-144) containing 10-aa sites in the amino-terminal region of Btk, were amplified from the corresponding cDNAs, whereas just carboxyl-terminal to the PH domain. We suggest that Btk those of mouse Lyn (64-124) and mouse Hck (60-116) were is on the pathway of signaling by which fyn, lyn, and hck amplified by reverse transcriptase-PCR using polyadenylyl- control cellular events. ated mRNAs isolated from BALB/c mouse spleen. These various DNA fragments were ligated in-frame to the pGex2T The publication costs of this article were defrayed in part by page charge Abbreviations: Btk, Bruton's tyrosine kinase; SH, Src homology; payment. This article must therefore be hereby marked "advertisement" GST, glutathione S-transferase; IPTG, isopropyl ,-D-thiogalacto- in accordance with 18 U.S.C. §1734 solely to indicate this fact. side; PH, pleckstrin homology. 8152 Cell Biology: Cheng et al. Proc. Natl. Acad. Sci. USA 91 (1994) 8153 vector and were sequenced using a primer derived from the of the human FYN gene; it contained the SH3 domain and a vector. Glutathione S-transferase (GST)-SH3 fusion proteins portion of the SH2 domain. were purified from isopropyl 3-D-thiogalactoside (IPTG)- To test whether Fyn can interact directly with Btk, in vitro induced bacterial lysates and were subsequently biotinylated filter binding assays were performed. The cDNA fragment as described (13, 14). from the isolated clone was transferred into the vector Solution Binding Assays. One liter of IPTG-induced bacte- pGex-lZT, which can express in bacteria GST fusion pro- ria expressing either GST or GST-Hck-SH3 was lysed in 10 teins in the same frame as the LexA fusion proteins of yeast. ml of ice-cold lysis buffer (PBS/100 mM EDTA/1% Triton The GST fusion protein containing the amino-terminal por- X-100/1% aprotinin/1 mM phenylmethylsulfonyl fluoride) tion of human Fyn (GST-Fyn-N) was purified and biotiny- by sonication. The supernatants were incubated with 250 ,Ld lated as described (13, 14). Total IPTG-induced bacterial cell of glutathione-agarose for 30 min at 40C. These GST- or lysates expressing the GST fusion protein containing the GST-Hck-SH3-saturated agarose beads were then washed full-length Btk (GST-Btk-F) were fractionated by SDS/ four times with the lysis buffer and stored in an equal volume PAGE, transferred to nitrocellulose, and probed with biotin- of PBS. To produce and detect Btk, we used a mammalian ylated GST-Fyn-N fusion peptides. The GST-Fyn-N probe expression construct, pGD-BTK-FLU, made by ligating the specifically recognized the GST-Btk-F protein but not the full-length coding region of Btk cDNA in-frame to the 5' end GST alone (Fig. 1), showing that the amino-terminal portion of the influenza hemagglutinin tag (FLU) in the retrovirus of Fyn interacts directly with Btk. vector pGD-FLU. To create Btk(4A) mutations, PCR muta- When GST-Fyn-N was used to probe fragments ofBtk, the genesis was performed (15). Approximately 2 x 107 293 cells amino-terminal fragment, Btk-N, was recognized but Btk-H, either untransfected or transiently transfected with pGD- which lacked only 44 carboxyl-terminal amino acids of BTK-FLU or pGD-BTK(4A)-FLU were lysed in 1 ml of the Btk-N, did not bind (Fig. 1). A fragment of Itk similar to lysis buffer (1% Nonidet P-40/150 mM NaCl/20 mM Hepes, Btk-N was also tested and was bound by the GST-Fyn-N pH 7.5/10 mM NaF/0.4 mM EDTA/50 mM Na3VO4/1 mM probe as strongly as was the Btk fragment (9). These results phenylmethylsulfonyl fluoride/1 mM leupeptin/1% aproti- indicate that Btk can interact with Fyn through a relatively nin) on ice for 30 min.
Recommended publications
  • Calycosin Down-Regulates C-Met to Suppress Development of Glioblastomas
    J Biosci (2019) 44:96 Ó Indian Academy of Sciences DOI: 10.1007/s12038-019-9904-4 (0123456789().,-volV)(0123456789().,-volV) Calycosin down-regulates c-Met to suppress development of glioblastomas , XIAOHU NIE ,YUE ZHOU* ,XIAOBING LI,JIE XU,XUYAN PAN,RUI YIN and BIN LU Department of Neurosurgery, Huzhou Central Hospital, Huzhou, Zhejiang, People’s Republic of China *Corresponding author (Email, [email protected]) These authors contributed equally to this work. MS received 15 October 2018; accepted 9 June 2019; published online 7 August 2019 The antitumor effect of calycosin has been widely studied, but the targets of calycosin against glioblastomas are still unclear. In this study we focused on revealing c-Met as a potential target of calycosin suppressing glioblastomas. In this study, suppressed-cell proliferation and cell invasion together with induced-cell apoptosis appeared in calycosin-treated U251 and U87 cells. Under treatment of calycosin, the mRNA expression levels of Dtk, c-Met, Lyn and PYK2 were observed in U87 cells. Meanwhile a western blot assay showed that c-Met together with matrix metalloproteinases-9 (MMP9) and phosphorylation of the serine/threonine kinase AKT (p-AKT) was significantly down-regulated by calycosin. Furthermore, overexpressed c-Met in U87 enhanced the expression level of MMP9 and p-AKT and also improved cell invasion. Additionally, the expression levels of c-Met, MMP9 and p-AKT were inhibited by calycosin in c-Met overex- pressed cells. However, an AKT inhibitor (LY294002) only effected on MMP9 and p-AKT, not on c-Met. These data collectively indicated that calycosin possibility targeting on c-Met and exert an anti-tumor role via MMP9 and AKT.
    [Show full text]
  • Inhibition of DDR1-BCR Signalling by Nilotinib As a New Therapeutic
    Inhibition of DDR1-BCR signalling by nilotinib as a new therapeutic strategy for metastatic colorectal cancer Maya Jeitany, Cédric Leroy, Priscillia Tosti, Marie Lafitte, Jordy Le Guet, Valérie Simon, Debora Bonenfant, Bruno Robert, Fanny Grillet, Caroline Mollevi, et al. To cite this version: Maya Jeitany, Cédric Leroy, Priscillia Tosti, Marie Lafitte, Jordy Le Guet, et al.. Inhibition of DDR1- BCR signalling by nilotinib as a new therapeutic strategy for metastatic colorectal cancer. EMBO Molecular Medicine, Wiley Open Access, 2018, 10 (4), pp.e7918. 10.15252/emmm.201707918. hal- 01872978 HAL Id: hal-01872978 https://hal.archives-ouvertes.fr/hal-01872978 Submitted on 12 Jan 2021 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Distributed under a Creative Commons Attribution| 4.0 International License Research Article Inhibition of DDR1-BCR signalling by nilotinib as a new therapeutic strategy for metastatic colorectal cancer Maya Jeitany1,†, Cédric Leroy1,2,3,†, Priscillia Tosti1,†, Marie Lafitte1, Jordy Le Guet1, Valérie Simon1, Debora Bonenfant2, Bruno Robert4, Fanny Grillet5, Caroline Mollevi4, Safia El Messaoudi4, Amaëlle Otandault4, Lucile Canterel-Thouennon4, Muriel Busson4, Alain R Thierry4, Pierre Martineau4, Julie Pannequin5, Serge Roche1,*,† & Audrey Sirvent1,†,** Abstract The current clinical management involves surgical removal of the primary tumour, often associated with chemotherapy.
    [Show full text]
  • Inhibition of Src Family Kinases and Receptor Tyrosine Kinases by Dasatinib: Possible Combinations in Solid Tumors
    Published OnlineFirst June 13, 2011; DOI: 10.1158/1078-0432.CCR-10-2616 Clinical Cancer Molecular Pathways Research Inhibition of Src Family Kinases and Receptor Tyrosine Kinases by Dasatinib: Possible Combinations in Solid Tumors Juan Carlos Montero1, Samuel Seoane1, Alberto Ocaña2,3, and Atanasio Pandiella1 Abstract Dasatinib is a small molecule tyrosine kinase inhibitor that targets a wide variety of tyrosine kinases implicated in the pathophysiology of several neoplasias. Among the most sensitive dasatinib targets are ABL, the SRC family kinases (SRC, LCK, HCK, FYN, YES, FGR, BLK, LYN, and FRK), and the receptor tyrosine kinases c-KIT, platelet-derived growth factor receptor (PDGFR) a and b, discoidin domain receptor 1 (DDR1), c-FMS, and ephrin receptors. Dasatinib inhibits cell duplication, migration, and invasion, and it triggers apoptosis of tumoral cells. As a consequence, dasatinib reduces tumoral mass and decreases the metastatic dissemination of tumoral cells. Dasatinib also acts on the tumoral microenvironment, which is particularly important in the bone, where dasatinib inhibits osteoclastic activity and favors osteogenesis, exerting a bone-protecting effect. Several preclinical studies have shown that dasatinib potentiates the antitumoral action of various drugs used in the oncology clinic, paving the way for the initiation of clinical trials of dasatinib in combination with standard-of-care treatments for the therapy of various neoplasias. Trials using combinations of dasatinib with ErbB/HER receptor antagonists are being explored in breast, head and neck, and colorectal cancers. In hormone receptor–positive breast cancer, trials using combina- tions of dasatinib with antihormonal therapies are ongoing. Dasatinib combinations with chemother- apeutic agents are also under development in prostate cancer (dasatinib plus docetaxel), melanoma (dasatinib plus dacarbazine), and colorectal cancer (dasatinib plus oxaliplatin plus capecitabine).
    [Show full text]
  • Receptor Signaling and Syk in the Initiation of B-Cell Antigen
    Nonredundant Roles of Src-Family Kinases and Syk in the Initiation of B-Cell Antigen Receptor Signaling This information is current as Ondrej Stepanek, Peter Draber, Ales Drobek, Vaclav Horejsi of September 30, 2021. and Tomas Brdicka J Immunol 2013; 190:1807-1818; Prepublished online 18 January 2013; doi: 10.4049/jimmunol.1202401 http://www.jimmunol.org/content/190/4/1807 Downloaded from Supplementary http://www.jimmunol.org/content/suppl/2013/01/18/jimmunol.120240 Material 1.DC1 http://www.jimmunol.org/ References This article cites 75 articles, 32 of which you can access for free at: http://www.jimmunol.org/content/190/4/1807.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision by guest on September 30, 2021 • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2013 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Nonredundant Roles of Src-Family Kinases and Syk in the Initiation of B-Cell Antigen Receptor Signaling Ondrej Stepanek, Peter Draber, Ales Drobek, Vaclav Horejsi, and Tomas Brdicka When a BCR on a mature B cell is engaged by its ligand, the cell becomes activated, and the Ab-mediated immune response can be triggered.
    [Show full text]
  • Activation Tyrosine Kinases, Btk and Lyn, in Mast Cell Redundant And
    Redundant and Opposing Functions of Two Tyrosine Kinases, Btk and Lyn, in Mast Cell Activation This information is current as Yuko Kawakami, Jiro Kitaura, Anne B. Satterthwaite, of September 25, 2021. Roberta M. Kato, Koichi Asai, Stephen E. Hartman, Mari Maeda-Yamamoto, Clifford A. Lowell, David J. Rawlings, Owen N. Witte and Toshiaki Kawakami J Immunol 2000; 165:1210-1219; ; doi: 10.4049/jimmunol.165.3.1210 Downloaded from http://www.jimmunol.org/content/165/3/1210 References This article cites 75 articles, 45 of which you can access for free at: http://www.jimmunol.org/content/165/3/1210.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists by guest on September 25, 2021 • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2000 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Redundant and Opposing Functions of Two Tyrosine Kinases, Btk and Lyn, in Mast Cell Activation1 Yuko Kawakami,* Jiro Kitaura,* Anne B. Satterthwaite,† Roberta M.
    [Show full text]
  • Protein Tyrosine Kinases: Their Roles and Their Targeting in Leukemia
    cancers Review Protein Tyrosine Kinases: Their Roles and Their Targeting in Leukemia Kalpana K. Bhanumathy 1,*, Amrutha Balagopal 1, Frederick S. Vizeacoumar 2 , Franco J. Vizeacoumar 1,3, Andrew Freywald 2 and Vincenzo Giambra 4,* 1 Division of Oncology, College of Medicine, University of Saskatchewan, Saskatoon, SK S7N 5E5, Canada; [email protected] (A.B.); [email protected] (F.J.V.) 2 Department of Pathology and Laboratory Medicine, College of Medicine, University of Saskatchewan, Saskatoon, SK S7N 5E5, Canada; [email protected] (F.S.V.); [email protected] (A.F.) 3 Cancer Research Department, Saskatchewan Cancer Agency, 107 Wiggins Road, Saskatoon, SK S7N 5E5, Canada 4 Institute for Stem Cell Biology, Regenerative Medicine and Innovative Therapies (ISBReMIT), Fondazione IRCCS Casa Sollievo della Sofferenza, 71013 San Giovanni Rotondo, FG, Italy * Correspondence: [email protected] (K.K.B.); [email protected] (V.G.); Tel.: +1-(306)-716-7456 (K.K.B.); +39-0882-416574 (V.G.) Simple Summary: Protein phosphorylation is a key regulatory mechanism that controls a wide variety of cellular responses. This process is catalysed by the members of the protein kinase su- perfamily that are classified into two main families based on their ability to phosphorylate either tyrosine or serine and threonine residues in their substrates. Massive research efforts have been invested in dissecting the functions of tyrosine kinases, revealing their importance in the initiation and progression of human malignancies. Based on these investigations, numerous tyrosine kinase inhibitors have been included in clinical protocols and proved to be effective in targeted therapies for various haematological malignancies.
    [Show full text]
  • Beyond TCR Signaling: Emerging Functions of Lck in Cancer and Immunotherapy
    Review Beyond TCR Signaling: Emerging Functions of Lck in Cancer and Immunotherapy Ursula Bommhardt, Burkhart Schraven and Luca Simeoni * Institute of Molecular and Clinical Immunology, Otto-von-Guericke University, Leipziger Strasse 44, 39120 Magdeburg, Germany * Correspondence: [email protected]; Tel. +49-391-6717894 Received: 12 June 2019; Accepted: 12 July 2019; Published: 16 July 2019 Abstract: In recent years, the lymphocyte-specific protein tyrosine kinase (Lck) has emerged as one of the key molecules regulating T-cell functions. Studies using Lck knock-out mice or Lck-deficient T-cell lines have shown that Lck regulates the initiation of TCR signaling, T-cell development, and T-cell homeostasis. Because of the crucial role of Lck in T-cell responses, strategies have been employed to redirect Lck activity to improve the efficacy of chimeric antigen receptors (CARs) and to potentiate T-cell responses in cancer immunotherapy. In addition to the well-studied role of Lck in T cells, evidence has been accumulated suggesting that Lck is also expressed in the brain and in tumor cells, where it actively takes part in signaling processes regulating cellular functions like proliferation, survival and memory. Therefore, Lck has emerged as a novel druggable target molecule for the treatment of cancer and neuronal diseases. In this review, we will focus on these new functions of Lck. Keywords: Lck; T cell; CAR; cancer; leukemia; brain 1. Introduction The lymphocyte-specific protein tyrosine kinase (Lck) is a member of the Src family of protein tyrosine kinases firstly identified in the 1980s [1,2]. Since then, the function of Lck has been extensively investigated and many mechanistic insights into the regulation of its activity have been revealed.
    [Show full text]
  • SRC-Family Kinases in Acute Myeloid Leukaemia and Mastocytosis
    cancers Review SRC-Family Kinases in Acute Myeloid Leukaemia and Mastocytosis Edwige Voisset , Fabienne Brenet , Sophie Lopez and Paulo de Sepulveda * INSERM U1068, CNRS UMR7258, Aix-Marseille Université UM105, Institute Paoli-Calmettes, CRCM—Cancer Research Center of Marseille, U1068 Marseille, France; [email protected] (E.V.); [email protected] (F.B.); [email protected] (S.L.) * Correspondence: [email protected] Received: 28 May 2020; Accepted: 19 July 2020; Published: 21 July 2020 Abstract: Protein tyrosine kinases have been recognized as important actors of cell transformation and cancer progression, since their discovery as products of viral oncogenes. SRC-family kinases (SFKs) play crucial roles in normal hematopoiesis. Not surprisingly, they are hyperactivated and are essential for membrane receptor downstream signaling in hematological malignancies such as acute myeloid leukemia (AML) and mastocytosis. The precise roles of SFKs are difficult to delineate due to the number of substrates, the functional redundancy among members, and the use of tools that are not selective. Yet, a large num ber of studies have accumulated evidence to support that SFKs are rational therapeutic targets in AML and mastocytosis. These two pathologies are regulated by two related receptor tyrosine kinases, which are well known in the field of hematology: FLT3 and KIT. FLT3 is one of the most frequently mutated genes in AML, while KIT oncogenic mutations occur in 80–90% of mastocytosis. Studies on oncogenic FLT3 and KIT signaling have shed light on specific roles for members of the SFK family. This review highlights the central roles of SFKs in AML and mastocytosis, and their interconnection with FLT3 and KIT oncoproteins.
    [Show full text]
  • Facial Cutaneo-Mucosal Venous Malformations Can Develop
    Brahami et al. Journal of Negative Results in BioMedicine (2017) 16:9 DOI 10.1186/s12952-017-0072-5 BRIEFREPORT Open Access Facial cutaneo-mucosal venous malformations can develop independently of mutation of TEK gene but may be associated with excessive expression of Src and p-Src Nabila Brahami1, Selvakumar Subramaniam2, Moudjahed Saleh Al-Ddafari1, Cecile Elkaim3, Pierre-Olivier Harmand3, Badr-Eddine Sari1,4, Gérard Lefranc5 and Mourad Aribi1* Abstract We aimed to search for mutations in the germline and somatic DNA of the TEK gene and to analyze the expression level of Src and phospho-Src (p-Src) in tumor and healthy tissues from patients with facial cutaneo-mucosal venous malformations (VMCM). Eligible patients from twelve families and thirty healthy controls were recruited respectively at the Departments of Stomatology and Oral Surgery, and Transfusion Medicine of Tlemcen University Medical Centre. Immunoblot analyses of Src and p-Src were performed after direct DNA sequencing. No somatic or germline mutations werefoundinallthe23exonsandtheir5’ and 3’ intronic flanking regions, except for one case in which a c.3025+20- 3025+22 del mutation was highlighted at the intron 15, both in the germline and somatic DNA. Additionally, elevated expression levels of Src and p-Src were observed only in the patient with such mutation. However, when normalized to β-actin, the overall relative expression levels of both Src and p-Src were significantly increased in VMCM tissues when compared to healthy tissues (for both comparisons, p <0.001). In conclusion, we confirm the outcomes of our previous work suggesting that VMCM can develop independently of mutation of the TEK gene.
    [Show full text]
  • Tyrosine Kinases As Targets for the Treatment of Rheumatoid Arthritis Christina D’Aura Swanson, Ricardo T
    REVIEWS Tyrosine kinases as targets for the treatment of rheumatoid arthritis Christina D’Aura Swanson, Ricardo T. Paniagua, Tamsin M. Lindstrom and William H. Robinson Abstract | As critical regulators of numerous cell signaling pathways, tyrosine kinases are implicated in the pathogenesis of several diseases, including rheumatoid arthritis (RA). In the absence of disease, synoviocytes produce factors that provide nutrition and lubrication for the surrounding cartilage tissue; few cellular infiltrates are seen in the synovium. In RA, however, macrophages, neutrophils, T cells and B cells infiltrate the synovium and produce cytokines, chemokines and degradative enzymes that promote inflammation and joint destruction. In addition, the synovial lining expands owing to the proliferation of synoviocytes and infiltration of inflammatory cells to form a pannus, which invades the surrounding bone and cartilage. Many of these cell responses are regulated by tyrosine kinases that operate in specific signaling pathways, and inhibition of a number of these kinases might be expected to provide benefit in RA. D’Aura Swanson, C. et al. Nat. Rev. Rheumatol. 5, 317–324 (2009); doi:10.1038/nrrheum.2009.82 Introduction Rheumatoid arthritis (RA) is an autoimmune synovitis that tyrosine kinases (RTKs) and non­receptor tyrosine kinases affects 0.5% of the population and can result in disability (non­rTKs).3 In addition to an extracellular ligand­binding owing to joint destruction.1 A number of cellular responses domain and a membrane­spanning domain, RTKs usually are thought to be involved in the pathogenesis of RA. An possess an intracellular cytoplasmic domain that contains adaptive autoimmune response mediated by T cells and a kinase core and regulatory sequences.
    [Show full text]
  • The Transcriptional Roles of ALK Fusion Proteins in Tumorigenesis
    cancers Review The Transcriptional Roles of ALK Fusion Proteins in Tumorigenesis 1, 2, , 1, Stephen P. Ducray y , Karthikraj Natarajan y z, Gavin D. Garland z, 1, , 2,3, , Suzanne D. Turner * y and Gerda Egger * y 1 Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Cambridge CB20QQ, UK 2 Department of Pathology, Medical University Vienna, 1090 Vienna, Austria 3 Ludwig Boltzmann Institute Applied Diagnostics, 1090 Vienna, Austria * Correspondence: [email protected] (S.D.T.); [email protected] (G.E.) European Research Initiative for ALK-related malignancies; www.erialcl.net. y These authors contributed equally to this work. z Received: 7 June 2019; Accepted: 23 July 2019; Published: 30 July 2019 Abstract: Anaplastic lymphoma kinase (ALK) is a tyrosine kinase involved in neuronal and gut development. Initially discovered in T cell lymphoma, ALK is frequently affected in diverse cancers by oncogenic translocations. These translocations involve different fusion partners that facilitate multimerisation and autophosphorylation of ALK, resulting in a constitutively active tyrosine kinase with oncogenic potential. ALK fusion proteins are involved in diverse cellular signalling pathways, such as Ras/extracellular signal-regulated kinase (ERK), phosphatidylinositol 3-kinase (PI3K)/Akt and Janus protein tyrosine kinase (JAK)/STAT. Furthermore, ALK is implicated in epigenetic regulation, including DNA methylation and miRNA expression, and an interaction with nuclear proteins has been described. Through these mechanisms, ALK fusion proteins enable a transcriptional programme that drives the pathogenesis of a range of ALK-related malignancies. Keywords: ALK; ALCL; NPM-ALK; EML4-ALK; NSCLC; ALK-translocation proteins; epigenetics 1. Introduction Anaplastic lymphoma kinase (ALK) was first successfully cloned in 1994 when it was reported in the context of a fusion protein in cases of anaplastic large cell lymphoma (ALCL) [1].
    [Show full text]
  • Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy
    cancers Review Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy 1,2, 3,4 1 2 3, Charles Pottier * , Margaux Fresnais , Marie Gilon , Guy Jérusalem ,Rémi Longuespée y 1, and Nor Eddine Sounni y 1 Laboratory of Tumor and Development Biology, GIGA-Cancer and GIGA-I3, GIGA-Research, University Hospital of Liège, 4000 Liège, Belgium; [email protected] (M.G.); [email protected] (N.E.S.) 2 Department of Medical Oncology, University Hospital of Liège, 4000 Liège, Belgium; [email protected] 3 Department of Clinical Pharmacology and Pharmacoepidemiology, University Hospital of Heidelberg, 69120 Heidelberg, Germany; [email protected] (M.F.); [email protected] (R.L.) 4 German Cancer Consortium (DKTK)-German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany * Correspondence: [email protected] Equivalent contribution. y Received: 17 January 2020; Accepted: 16 March 2020; Published: 20 March 2020 Abstract: Receptor tyrosine kinases (RTKs) are key regulatory signaling proteins governing cancer cell growth and metastasis. During the last two decades, several molecules targeting RTKs were used in oncology as a first or second line therapy in different types of cancer. However, their effectiveness is limited by the appearance of resistance or adverse effects. In this review, we summarize the main features of RTKs and their inhibitors (RTKIs), their current use in oncology, and mechanisms of resistance. We also describe the technological advances of artificial intelligence, chemoproteomics, and microfluidics in elaborating powerful strategies that could be used in providing more efficient and selective small molecules inhibitors of RTKs.
    [Show full text]